Logo image of AEON

AEON BIOPHARMA INC (AEON) Stock Fundamental Analysis

NYSEARCA:AEON - NYSE Arca - US00791X2099 - Common Stock - Currency: USD

0.812  -0.03 (-3.24%)

After market: 0.8095 0 (-0.31%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AEON. AEON was compared to 0 industry peers in the Unkown industry. Both the profitability and financial health of AEON have multiple concerns. AEON does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AEON was profitable.
AEON had a negative operating cash flow in the past year.
In the past 5 years AEON reported 4 times negative net income.
AEON had a negative operating cash flow in each of the past 5 years.
AEON Yearly Net Income VS EBIT VS OCF VS FCFAEON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA 1225.58%
ROE N/A
ROIC 2246.03%
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEON Yearly ROA, ROE, ROICAEON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

AEON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEON Yearly Profit, Operating, Gross MarginsAEON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 2K 4K

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for AEON has been increased compared to 1 year ago.
AEON has less shares outstanding than it did 5 years ago.
The debt/assets ratio for AEON is higher compared to a year ago.
AEON Yearly Shares OutstandingAEON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
AEON Yearly Total Debt VS Total AssetsAEON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.72, we must say that AEON is in the distress zone and has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.72
ROIC/WACCN/A
WACCN/A
AEON Yearly LT Debt VS Equity VS FCFAEON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

2.3 Liquidity

A Current Ratio of 1.43 indicates that AEON should not have too much problems paying its short term obligations.
A Quick Ratio of 1.43 indicates that AEON should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.43
AEON Yearly Current Assets VS Current LiabilitesAEON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

AEON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 131.82%, which is quite impressive.
Measured over the past years, AEON shows a very strong growth in Earnings Per Share. The EPS has been growing by 56.13% on average per year.
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%101%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -49.88% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-101.33%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 100M 200M 300M 400M 500M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 40 -40 -60 -80

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.00, the valuation of AEON can be described as very cheap.
AEON's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.35.
The Forward Price/Earnings Ratio is negative for AEON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0
Fwd PE N/A
AEON Price Earnings VS Forward Price EarningsAEON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.23
AEON Per share dataAEON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100 150 200 250

4.3 Compensation for Growth

A cheap valuation may be justified as AEON's earnings are expected to decrease with -26.16% in the coming years.
PEG (NY)N/A
PEG (5Y)0
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AEON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEON BIOPHARMA INC

NYSEARCA:AEON (7/24/2025, 8:20:38 PM)

After market: 0.8095 0 (-0.31%)

0.812

-0.03 (-3.24%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change2.32%
Market Cap30.17M
Analysts82.86
Price Target187.27 (22962.81%)
Short Float %4.61%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-49%
PT rev (3m)-49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.23
EPS(TTM)298.79
EY36796.8%
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS-0.3
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)0
Profitability
Industry RankSector Rank
ROA 1225.58%
ROE N/A
ROCE 2843.07%
ROIC 2246.03%
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.09
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 1.43
Altman-Z -6.72
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%101%
EPS Next Y-101.33%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y339.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.24%
OCF growth 3YN/A
OCF growth 5YN/A